Every material Form 8-K USANA HEALTH SCIENCES INC has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
USANA reported third-quarter 2026 net sales of $206 million, down from $214 million a year earlier, while its net loss narrowed to $(5.6) million from $(6.5) million. The company lowered its fiscal 2026 outlook, now expecting consolidated net sales approaching $900 million (previously $910 million) and Adjusted EBITDA of $77 million (previously $80.5 million, as corrected), and it also expects a larger full-year net loss of $(16) million, versus $(11) million previously.
Q3 2026 net sales of $206 million, down 4% year over year; Adjusted EBITDA of $12.1 million, down 13%
Net loss of $(5.6) million and diluted EPS of $(0.30), compared with $(0.36) a year earlier
Fiscal 2026 outlook: net sales approaching $900 million (from $910 million); net loss $(16) million (from $(11) million); diluted EPS $(0.90) (from $(0.61))
Company corrected prior Adjusted EBITDA: second quarter 2026 reduced from $27.8 million to $21.7 million; cash and equivalents $179 million with no debt
USANA Health Sciences amended its $75 million revolving credit facility on September 30, 2026, with Bank of America as administrative agent, and the facility matures June 27, 2030. The amendment sets a minimum trailing four-quarter Consolidated EBITDA covenant of $100 million starting with the quarter ending October 3, 2026, which drops to $70 million when revolving exposure is $50 million or less, and raises the annual general asset sale basket from $500,000 to $2.5 million.
Revolving credit facility of $75 million, maturing June 27, 2030, with an option to increase by more than $200 million on request
Minimum Consolidated EBITDA covenant of $100 million, reduced to $70 million when lender revolving exposure is $50 million or less
Annual general asset sale basket raised from $500,000 to $2.5 million
New permission for USANA Australia Pty, Ltd to sell Sydney, Australia real property; sale and leaseback transactions remain generally prohibited
USANA Health Sciences reported second-quarter 2026 net sales of $223 million, down from $236 million a year earlier, and a net loss attributable to the company of $21.4 million, compared with net earnings of $9.7 million. The loss includes an estimated preliminary non-cash impairment charge of $29.1 million tied to Hiya, and the company lowered its fiscal 2026 outlook, now projecting a full-year net loss of $11 million versus its prior expectation of net earnings of $20 million to $27 million.
Q2 2026 diluted EPS was $(1.16) versus $0.52; adjusted diluted EPS was $(0.07) versus $0.74.
Hiya net sales were $28 million, down 17% year over year, and Rise Wellness net sales were $3 million, up 40%.
Fiscal 2026 guidance: consolidated net sales of $910 million (previously $925 million to $1.0 billion) and adjusted EBITDA of $87 million (previously $101 million to $109 million).
The company ended the quarter with $169 million in cash and zero debt and reported $20 million in free cash flow.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every USANA HEALTH SCIENCES INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →